Equities analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings per share (EPS) of ($1.35) for the current quarter, according to Zacks. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.38) to ($1.31). Atara Biotherapeutics posted earnings per share of ($1.60) in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.6%. The firm is scheduled to issue its next earnings results on Thursday, August 13th.
On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.63) per share for the current financial year, with EPS estimates ranging from ($5.34) to ($4.14). For the next year, analysts expect that the business will post earnings of ($4.35) per share, with EPS estimates ranging from ($5.29) to ($3.26). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.21.
In other Atara Biotherapeutics news, CEO Pascal Touchon sold 12,135 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $12.92, for a total transaction of $156,784.20. Following the transaction, the chief executive officer now owns 264,844 shares of the company’s stock, valued at $3,421,784.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.
Several hedge funds have recently modified their holdings of the business. Redmile Group LLC boosted its stake in shares of Atara Biotherapeutics by 13.9% during the first quarter. Redmile Group LLC now owns 5,293,370 shares of the biotechnology company’s stock worth $45,047,000 after buying an additional 644,800 shares during the period. Maverick Capital Ltd. boosted its stake in shares of Atara Biotherapeutics by 4.9% during the first quarter. Maverick Capital Ltd. now owns 5,199,897 shares of the biotechnology company’s stock worth $44,251,000 after buying an additional 241,466 shares during the period. Morgan Stanley boosted its stake in shares of Atara Biotherapeutics by 18.1% during the first quarter. Morgan Stanley now owns 3,462,329 shares of the biotechnology company’s stock worth $29,463,000 after buying an additional 529,482 shares during the period. Bridger Management LLC boosted its stake in shares of Atara Biotherapeutics by 10.2% during the fourth quarter. Bridger Management LLC now owns 2,932,865 shares of the biotechnology company’s stock worth $48,304,000 after buying an additional 271,845 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Atara Biotherapeutics by 26.5% during the first quarter. Federated Hermes Inc. now owns 2,889,541 shares of the biotechnology company’s stock worth $24,590,000 after buying an additional 605,068 shares during the period.
Shares of NASDAQ ATRA traded up $0.32 during mid-day trading on Tuesday, hitting $13.84. The company had a trading volume of 1,999,800 shares, compared to its average volume of 1,185,467. The company has a market capitalization of $797.03 million, a PE ratio of -2.53 and a beta of 2.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.27 and a quick ratio of 7.27. Atara Biotherapeutics has a 1-year low of $4.52 and a 1-year high of $21.45. The business’s 50-day simple moving average is $11.38 and its 200 day simple moving average is $11.92.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: What is a resistance level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.